Cite
ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients
MLA
Alicja E. Grzegorzewska, et al. “ENHO, RXRA, and LXRA Polymorphisms and Dyslipidaemia, Related Comorbidities and Survival in Haemodialysis Patients.” BMC Medical Genetics, vol. 19, Nov. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....88324f2d9d8edaf1e501f60925957a9b&authtype=sso&custid=ns315887.
APA
Alicja E. Grzegorzewska, Leszek Niepolski, Paweł P. Jagodziński, Ireneusz Stolarek, Monika K. Świderska, Wojciech Warchoł, Adrianna Mostowska, & Marek Figlerowicz. (2018). ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients. BMC Medical Genetics, 19.
Chicago
Alicja E. Grzegorzewska, Leszek Niepolski, Paweł P. Jagodziński, Ireneusz Stolarek, Monika K. Świderska, Wojciech Warchoł, Adrianna Mostowska, and Marek Figlerowicz. 2018. “ENHO, RXRA, and LXRA Polymorphisms and Dyslipidaemia, Related Comorbidities and Survival in Haemodialysis Patients.” BMC Medical Genetics 19 (November). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....88324f2d9d8edaf1e501f60925957a9b&authtype=sso&custid=ns315887.